Iterum Therapeutics (ITRM)

[exwannabe]

There numbers on dates and dollars look reasonable, though will be a bit tight so I would not be surprised with a modest raise in a year or so if the PPS supports it.

For the trial, I really hope they run a trial in patients not suitable for cipro with solupenam vs all comers with a non-inferiority endpoint. They might know enough to select a better subset, but that will be a smaller label so less upside.

Next significant news should be late Dec or early next year when they disclose the trial details.